Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose safety and pharmacokinetic study of sotatercept in healthy Japanese adults
jRCT2051220078Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of sotatercept in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Merck & Co. Primary endpoints: Adverse events and MK-7962 pharmacokinetics. Started Sep 2022; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2051220078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220078.